| Literature DB >> 35984684 |
Zixin Wang1, Joseph Tak Fai Lau1,2,3,4, Pei Qin5,1, Jianmei He6, Xue Yang1, Siyu Chen1, Xi Chen6, Hui Jiang1, Ada Wai Tung Fung7.
Abstract
BACKGROUND: Neurocognitive impairments are prevalent among older people in China. It is more problematic among older people living with HIV.Entities:
Keywords: HIV; HIV sero-status; depression; depressive symptoms; level of physical activity; mediation effects; mental health; neurocognitive; neurocognitive performance; physical activity; public health
Mesh:
Year: 2022 PMID: 35984684 PMCID: PMC9440416 DOI: 10.2196/32968
Source DB: PubMed Journal: JMIR Public Health Surveill ISSN: 2369-2960
Figure 1Mediation effects of physical activity and depressive symptoms in the association between HIV status and cognitive function (z-score); *: P<.05; **: P<.01; ***: P<.001. The path analysis presented the standardized regression weights and P value of each path.
Characteristics of older people living with HIV and HIV-negative controls.
| Characteristics | Older people living with HIV (n=315), mean (SD) | HIV-negative controls (n=350) | ||||||
|
|
| |||||||
|
| Age (years), mean (SD) | 61.3 (6.8) | 61.1 (6.4) | .62 | ||||
|
|
| .53 | ||||||
|
|
| Male | 230 (73.0) | 257 (73.4) |
| |||
|
|
| Female | 85 (27.0) | 83 (23.6) |
| |||
|
| Years of education, mean (SD) | 5.7 (3.6) | 5.5 (3.4) | .48 | ||||
|
|
| .09 | ||||||
|
|
| Han | 307 (97.5) | 347 (99.1) |
| |||
|
|
| Others | 8 (2.5) | 3 (0.9) |
| |||
|
|
| <.001 | ||||||
|
|
| Married | 215 (68.3) | 303 (86.8) |
| |||
|
|
| Widowed | 72 (22.9) | 29 (8.3) |
| |||
|
|
| Divorced or single | 28 (8.9) | 17 (4.9) |
| |||
|
|
| .59 | ||||||
|
|
| ≤10,000a | 163 (52.1) | 187 (54.2) |
| |||
|
|
| >10,000 | 150 (47.9) | 158 (45.8) |
| |||
|
|
| <.001 | ||||||
|
|
| No | 224 (71.1) | 310 (88.8) |
| |||
|
|
| Yes | 91 (28.9) | 39 (11.2) |
| |||
|
|
| |||||||
|
| Score of CES-D-20b, mean (SD) | 17.4 (13.0) | 9.4 (9.4) | <.001 | ||||
|
| <.001 | |||||||
|
|
| Low | 61 (19.4) | 32 (9.2) |
| |||
|
|
| Moderate | 140 (44.4) | 115 (32.9) |
| |||
|
|
| High | 114 (36.2) | 202 (57.7) |
| |||
|
|
| |||||||
|
| Hypertension | 162 (51.4) | 196 (56.0) | .24 | ||||
|
| Diabetes | 23 (7.3) | 24 (6.9) | .81 | ||||
|
| Hyperlipidemia | 12 (3.8) | 12 (3.4) | .84 | ||||
|
| Chronic bronchitis | 26 (8.3) | 21 (6.0) | .29 | ||||
|
| Chronic obstructive pulmonary disease | 7 (2.2) | 4 (1.1) | .27 | ||||
|
| Cerebrovascular disease | 22 (7.0) | 24 (6.9) | .94 | ||||
|
| Coronary heart disease | 15 (4.8) | 21 (6.0) | .48 | ||||
|
| Myocardial infarction | 1 (0.3) | 3 (0.9) | .63 | ||||
|
| Hepatitis B | 23 (7.3) | 2 (0.6) | <.001 | ||||
|
| Hepatitis C | 1 (0.3) | 0 (0.0) | .47 | ||||
|
| Liver dysfunction | 15 (4.8) | 3 (0.9) | .002 | ||||
|
| Liver cirrhosis | 5 (1.6) | 0 (0.0) | .02 | ||||
|
| Chronic kidney disease | 12 (3.8) | 6 (1.7) | .09 | ||||
|
| Peptic ulcer disease | 31 (9.9) | 27 (7.7) | .33 | ||||
|
| Cancer | 15 (4.8) | 6 (1.7) | .02 | ||||
|
| Peripheral vascular disease | 13 (4.1) | 5 (1.4) | .03 | ||||
|
| Connective tissue disease | 26 (8.3) | 23 (6.6) | .39 | ||||
|
| Number of chronic conditions, mean (SD) | 1.3 (1.2) | 1.1 (1.2) | .07 | ||||
|
|
| |||||||
|
| Number of medication usec, mean (SD) | 0.3 (0.6) | 0.3 (0.7) | .12 | ||||
|
| ||||||||
|
|
| |||||||
|
|
| <1 year | 100 (31.7) | N/Ad | N/A | |||
|
|
| 1-3 years | 150 (47.6) | N/A |
| |||
|
|
| ≥4 years | 65 (20.6) | N/A | N/A | |||
|
|
|
| ||||||
|
|
| <350 | 177 (56.4) | N/A | N/A | |||
|
|
| 350-500 | 70 (22.3) | N/A | N/A | |||
|
|
| >500 | 67 (21.3) | N/A | N/A | |||
|
|
|
| ||||||
|
|
| <200 | 109 (34.6) | N/A | N/A | |||
|
|
| 200-350 | 77 (24.4) | N/A | N/A | |||
|
|
| 350-500 | 20 (6.4) | N/A | N/A | |||
|
|
| >500 | 8 (2.5) | N/A | N/A | |||
|
|
| Missing | 101 (32.1) | N/A | N/A | |||
|
|
| |||||||
|
|
| Yes | 298 (97.8) | N/A | N/A | |||
|
|
| No | 7 (2.2) | N/A | N/A | |||
|
|
| |||||||
|
|
| Yes | 67 (21.9) | N/A | N/A | |||
|
|
| No | 241 (78.1) | N/A | N/A | |||
a10,000 RMB= US $1507.
bCES-D-20: 20-item Center for Epidemiological Studies-Depression.
cThe number of medications were constructed by counting the number of affirmative item responses on whether they are taking other medications, including diabetes medication, lipid-lowering drugs, aspirin, warfarin, drugs for heart disease, antidepressants, antidementia drugs, and nonsteroidal anti-inflammatory drugs.
dN/A: not applicable.
eCD4: cluster of differentiation 4.
fART: antiretroviral therapy.
Difference in raw scores of neurocognitive tests and z-scores of global or domain of neurocognitive performance between older people living with HIV and HIV-negative controls.
| Neurocognitive domains | Older people living with HIV (n=315), mean (SD) | HIV-negative controls (n=350), mean (SD) | Crude | Adjusted | |||
|
|
|
| |||||
|
| CAVLTc–total learning (raw score) | 30.41 (10.54) | 36.65 (9.38) | <.001 | <.001 | ||
|
| Domain | –0.66 (1.12) | 0 (1) | <.001 | <.001 | ||
|
|
|
| |||||
|
| CAVLT–delayed recall (raw score) | 5.64 (3.06) | 7.59 (2.85) | <.001 | <.001 | ||
|
| Domain | –0.68 (1.08) | 0 (1) | <.001 | <.001 | ||
|
|
|
| |||||
|
| Animal (raw score) | 12.97 (3.51) | 13.45 (3.07) | .06 | .02 | ||
|
| Fruits (raw score) | 8.98 (2.77) | 9.65 (2.63) | .003 | <.001 | ||
|
| Vegetable (raw score) | 10.60 (3.17) | 11.34 (3.16) | .002 | .001 | ||
|
| Domain | –0.21 (0.85) | 0 (0.77) | .001 | <.001 | ||
|
|
|
| |||||
|
| Digit span—forward (raw score) | 7.87 (2.61) | 8.64 (2.60) | <.001 | <.001 | ||
|
| Digit span—backward (raw score) | 3.71 (1.83) | 4.13 (2.75) | .02 | .01 | ||
|
| Visual span—forward (raw score) | 6.69 (1.67) | 7.07 (1.59) | .003 | .004 | ||
|
| Visual span—backward (raw score) | 4.63 (2.03) | 4.89 (1.78) | .08 | .08 | ||
|
| Domain | –0.21 (0.70) | 0 (0.69) | <.001 | .002 | ||
|
|
|
| |||||
|
| CTMT-Ae (raw score) | 22.82 (20.27) | 16.40 (10.99) | <.001 | <.001 | ||
|
| Domain | –0.58 (1.84) | 0 (1) | <.001 | <.001 | ||
|
|
|
| |||||
|
| CTMT-Bf (raw score) | 140.70 (123.69) | 110.01 (94.46) | .001 | .001 | ||
|
| Domain | –0.32 (1.31) | 0 (1) | .001 | .001 | ||
|
|
|
| |||||
|
| Dominant hand (raw score) | 113.99 (48.68) | 104.36 (43.55) | .02 | .02 | ||
|
| Non-dominant hand (raw score) | 123.04 (101.07) | 108.57 (38.65) | .01 | .01 | ||
|
| Domain | –0.30 (1.62) | 0 (0.96) | .01 | .01 | ||
|
| Global cognitive | –0.36 (0.73) | 0 (0.58) | <.001 | <.001 | ||
aP values obtained by univariate linear regression models.
bAdjusted for confounders—age, sex, years of formal education, marital status, personal annual income, living arrangement (whether living alone or not), number of chronic conditions, and mediation use.
cCAVLT: Chinese Auditory Verbal Learning Test.
dz-scores of individual tests were calculated by using the following formula: (raw test score – mean test score among HIV-negative control) / SD of test score among HIV-negative controls. Domain z-scores were calculated by averaging z-scores of the tests within the respective domain.
eCTMT-A: Chinese Trail Making Test Part A.
fCTMT-B: Chinese Trail Making Test Part B.
gGlobal z-scores were calculated by averaging z-scores in all tests used in this study.
Model fit and indirect effects of the proposed mediation model
| Dependent variable | CFIa | Total effect, | Indirect effect, | Indirect effect (physical activity), | Indirect effect (depression), | PMc |
| Learning (domain | 0.93 | –.68 (–.83, –.55) | –.13 (–.20, –.07) | –.04 (–.09, –.01) | –.09 (–.15, –.04) | 19% |
| Memory (domain | 0.92 | –.70 (–.84, –.56) | –.12 (–.18, –.06) | –.04 (–.08, –.01) | –.08 (–.13, –.03) | 17% |
| Verbal fluency (domain | 0.91 | –.23 (–.35, –.11) | –.07 (–.13, –.02) | –.04 (–.08, –.01) | –.03 (–.08, .01) | 31% |
| Attention or working memory (domain | 0.93 | –.22 (–.31, –.13) | –.02 (–.06, .01) | .001 (–.02, .02) | –.02 (–.06, .006) | 11% |
| Processing speed (domain | 0.92 | –.61 (–.84, –.41) | –.10 (–.22, –.02) | –.001 (–.05, .05) | –.10 (–.22, –.02) | 17% |
| Executive function (domain | 0.91 | –.35 (–.53, –.17) | –.03 (–.13, .04) | .01 (–.03, .04) | –.04 (–.13, .03) | 9% |
| Motor skills (domain | 0.91 | –.29 (–.55, –.13) | –.05 (–.13, .07) | –.01 (–.06, .04) | –.04 (–.10, .03) | 18% |
| Global | 0.93 | –.35 (–.44, –.26) | –.06 (–.10, –.03) | –.02 (–.04, .002) | –.04 (–.08, .02) | 17% |
aCFI: Comparative Fit Index.
b95% bias-corrected confidence intervals were presented (bootstrap sample size=2000), which did not include 0, showing the mediation effect was statistically significant (P<.05). The results were reported after controlling for significant background variables (P<.10) and other potential confounders.
cPM: percent mediated.